Abstract

Chronic lithium administration for the treatment of bipolar disorder leads to nephrogenic diabetes insipidus (NDI), characterized by polyuria, natriuresis, kaliuresis, and collecting duct remodeling and cell proliferation among other features. Previously, using a 2-week lithium-induced NDI model, we reported that P2Y2 receptor (R) knockout mice are significantly resistant to polyuria, natriuresis, kaliuresis, and decrease in AQP2 protein abundance in the kidney relative to wild type mice. Here we show this protection is long-lasting, and is also associated with significant amelioration of lithium-induced collecting duct remodeling and cell proliferation. Age-matched wild type and knockout mice were fed regular (n = 5/genotype) or lithium-added (40 mmol/kg chow; n = 10/genotype) diet for 5 months and euthanized. Water intake, urine output and osmolality were monitored once in every month. Salt blocks were provided to mice on lithium-diet to prevent sodium loss. At the end of 5 months mice were euthanized and serum and kidney samples were analyzed. There was a steady increase in lithium-induced polyuria, natriuresis and kaliuresis in wild type mice over the 5-month period. Increases in these urinary parameters were very low in lithium-fed knockout mice, resulting in significantly widening differences between the wild type and knockout mice. Terminal AQP2 and NKCC2 protein abundances in the kidney were significantly higher in lithium-fed knockout vs. wild type mice. There were no significant differences in terminal serum lithium or sodium levels between the wild type and knockout mice. Confocal immunofluorescence microscopy revealed that lithium-induced marked remodeling of collecting duct with significantly increased proportion of [H+]-ATPase-positive intercalated cells and decreased proportion of AQP2-positive principal cells in the wild type, but not in knockout mice. Lithium-induced collecting duct cell proliferation (indicated by Ki67 labeling), was significantly lower in knockout vs. wild type mice. This is the first piece of evidence that purinergic signaling is potentially involved in lithium-induced collecting duct remodeling and cell proliferation. Our results demonstrate that genetic deletion of P2Y2-R protects against the key structural and functional alterations in Li-induced NDI, and underscore the potential utility of targeting this receptor for the treatment of NDI in bipolar patients on chronic lithium therapy.

Highlights

  • About 4% of the 21.8 million United States Veterans suffer from bipolar disorder, a sequel of post-traumatic stress disorder (PTSD)

  • In the P2Y2 KO mice, a modest increase in the Ki67-positive cells could be seen in the cortex, but not in the medulla after lithium-treatment. It appears that genetic deletion of P2Y2 receptor significantly protects against lithium-induced collecting duct proliferation. In this communication we documented that genetic deletion of P2Y2 receptor offers long-term protection against lithium-induced polyuria, natriuresis, kaliuresis, decreases in AQP2 and Na-K-Cl co-transporter-2 (NKCC2) protein abundances in the renal medulla, collecting duct remodeling and proliferation of collecting duct cells

  • Assuming that there are no significant differences between genetic deletion and pharmacological blockade of P2Y2 receptor by a selective and potent P2Y2 receptor antagonist when available, extrapolation of the significant observations made here in the 5-month model support the hypothesis that P2Y2 receptor antagonism may be a viable option for the treatment of lithium-induced nephrogenic diabetes insipidus (NDI) in humans

Read more

Summary

Introduction

About 4% of the 21.8 million United States Veterans suffer from bipolar disorder, a sequel of post-traumatic stress disorder (PTSD). About 30% of bipolar Veterans receive lithium therapy, where it has distinct advantages over the non-lithium drugs. Other drugs have not proven to be more efficacious than lithium in this respect (DeLa Crux et al, 2003; Ahearn et al, 2013). In recent years lithium has emerged as a robust neuroprotective agent for the treatment of acute brain injury and chronic neurodegenerative diseases (Rowe and Chuang, 2004; Wada et al, 2005; Quiroz et al, 2010; Florenza et al, 2012; Chiu et al, 2013). Beyond its current use in bipolar disorder, the neuroprotective ability of lithium implies it could be used to treat or prevent brain damage following acute injury, such as ischemic stroke or chronic neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, or Huntington’s disease

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.